These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 17439905

  • 21. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
    Cornblath DR, Bienen EJ, Blight AR.
    Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Sustained-release fampridine for multiple sclerosis.
    Bever CT, Judge SI.
    Expert Opin Investig Drugs; 2009 Jul; 18(7):1013-24. PubMed ID: 19548855
    [Abstract] [Full Text] [Related]

  • 24. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 25. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J.
    Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 29. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
    Wymer JP, Simpson J, Sen D, Bongardt S, Lacosamide SP742 Study Group.
    Clin J Pain; 2009 Jun; 25(5):376-85. PubMed ID: 19454870
    [Abstract] [Full Text] [Related]

  • 32. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
    Potter PJ, Hayes KC, Segal JL, Hsieh JT, Brunnemann SR, Delaney GA, Tierney DS, Mason D.
    J Neurotrauma; 1998 Oct; 15(10):837-49. PubMed ID: 9814639
    [Abstract] [Full Text] [Related]

  • 33. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Zörner B, Filli L, Reuter K, Kapitza S, Lörincz L, Sutter T, Weller D, Farkas M, Easthope CS, Czaplinski A, Weller M, Linnebank M.
    Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
    [Abstract] [Full Text] [Related]

  • 34. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP.
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [Abstract] [Full Text] [Related]

  • 36. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
    Mathiesen HK, Sorensen PS.
    Expert Rev Neurother; 2013 Dec; 13(12):1309-17. PubMed ID: 24236901
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 38. Fampridine-SR for multiple sclerosis and spinal cord injury.
    Hayes KC.
    Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
    [Abstract] [Full Text] [Related]

  • 39. [Efficacy and safety of Kinezia (fampridine) in the complex therapy of multiple sclerosis].
    Stolyarov ID, Petrov AM, Boyko AN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020 May; 120(11):45-52. PubMed ID: 33340297
    [Abstract] [Full Text] [Related]

  • 40. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial.
    Brodie MJ, Rosenfeld WE, Vazquez B, Sachdeo R, Perdomo C, Mann A, Arroyo S.
    Epilepsia; 2009 Aug; 50(8):1899-909. PubMed ID: 19490053
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.